What is the current market price of Tucatinib (Tucatinib)? Is it expensive?

Tucatinib, also known as tucatinib, is a targeted drug used to treat HER2-positive breast cancer. Although it has been widely used in European and American markets, the drug has not yet been officially marketed in my country and therefore cannot be included in the national medical insurance catalog. This also means that if patients want to use tucatinib, they must rely on overseas channels to purchase it. Not only is it more inconvenient to obtain, but the financial burden is also relatively large.

According to the latest data, the original drug of tucatinib sells at a relatively high price in the European market. Taking the specifications of 150mg*84 tablets as an example, the price per box is about more than 40,000 yuan, which is really expensive. For many breast cancer patients who require long-term medication, this price is undoubtedly a great financial pressure, especially without medical insurance reimbursement, which may be difficult to afford in the long term.

However, it is worth noting that there are currently generic versions of tucatinib on the market in overseas markets. For example, the generic drug 150mg*60 tablets launched by a Lao pharmaceutical factory sells for about more than 2,000 yuan. Although the number of generic drugs is slightly smaller, from a price comparison point of view, their cost is obviously more affordable. Generic drugs are usually basically the same as the original drugs in terms of drug ingredients, and their efficacy can also meet most clinical needs, so they have become a realistic choice for many patients.

To sum up, the original drug of tucatinib is relatively expensive and not suitable for all patients. However, as the marketing and channels of generic drugs gradually mature, more patients can obtain the drugs at a lower cost, thus reducing financial pressure without reducing the therapeutic effect. In the future, if tucatinib is approved for marketing in China and included in medical insurance, its price and accessibility may further improve.

Reference materials:https://www.drugs.com/